Glucagonoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
If left untreated, patients with glucagonoma may progress to develop [[necrolytic migratory erythema]], [[cheilosis]], [[stomatitis]], [[diarrhea]], [[polyuria]], and [[polydipsia]]. The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10-year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis. Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis. Age, grade, and distant metastases are the most significant predictors of survival. | If left untreated, patients with glucagonoma may progress to develop [[necrolytic migratory erythema]], [[cheilosis]], [[stomatitis]], [[diarrhea]], [[polyuria]], and [[polydipsia]]. The presence of [[metastasis]] is associated with a particularly poor prognosis among patients with glucagonoma. The 10-year event free survival rate is less than 51.6% with [[metastasis]] and 64.3% without [[metastasis]]. Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis. [[Age]], grade, and distant metastases are the most significant predictors of survival. | ||
==Natural History== | ==Natural History== | ||
*If left untreated, patients with glucagonoma may progress to develop [[necrolytic migratory erythema]], [[cheilosis]], [[stomatitis]], [[diarrhea]], [[polyuria]], and [[polydipsia]]. | *If left untreated, patients with glucagonoma may progress to develop [[necrolytic migratory erythema]], [[cheilosis]], [[stomatitis]], [[diarrhea]], [[polyuria]], and [[polydipsia]]. | ||
*Glucagonoma has a very slow growth rate compared to most malignant tumors. | *Glucagonoma has a very slow growth rate compared to most [[malignant tumors]]. | ||
== Complications == | == Complications == | ||
Complications of glucagonoma include: | Complications of glucagonoma include: | ||
* Metastasis: | * [[Metastasis]]: | ||
**Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis. | **Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis. | ||
**Metastasis occurs mainly in the [[liver]] but in few cases, it can occur in [[lymph nodes]], [[peritoneum]], [[lung]], and [[Adrenal gland|adrenals]]. | **[[Metastasis]] occurs mainly in the [[liver]] but in few cases, it can occur in [[lymph nodes]], [[peritoneum]], [[lung]], and [[Adrenal gland|adrenals]]. | ||
* Weight loss: due to the catabolic effect of [[glucagon]], most patients lose weight. | * [[Weight loss]]: due to the [[catabolic]] effect of [[glucagon]], most patients lose weight. | ||
* [[Anemia]] | * [[Anemia]] | ||
* Neuropsychiatric manifestations include [[depression]], [[dementia]], [[psychosis]], and [[agitation]] | * [[Neuropsychiatric]] manifestations include [[depression]], [[dementia]], [[psychosis]], and [[agitation]] | ||
* Reversible [[dilated cardiomyopathy]]<ref>{{Cite journal | * Reversible [[dilated cardiomyopathy]]<ref>{{Cite journal | ||
| author = [[K. Chang-Chretien]], [[J. T. Chew]] & [[D. P. Judge]] | | author = [[K. Chang-Chretien]], [[J. T. Chew]] & [[D. P. Judge]] | ||
| Line 31: | Line 31: | ||
==Prognosis== | ==Prognosis== | ||
Prognosis of glucagonoma depends on the following: | Prognosis of glucagonoma depends on the following: | ||
*Whether or not the tumor can be removed by surgery. | *Whether or not the [[tumor]] can be removed by [[surgery]]. | ||
*The | *The stage of the [[tumor]], the size of the [[tumor]], whether [[cancer]] has [[spread]] outside the [[pancreas]]. | ||
*The patient’s general health. | *The patient’s general health. | ||
*Whether the tumor has just been diagnosed or has recurred. | *Whether the [[tumor]] has just been diagnosed or has recurred. | ||
*The presence of [[metastasis]] is associated with a particularly poor prognosis among patients with glucagonoma. | *The presence of [[metastasis]] is associated with a particularly poor prognosis among patients with glucagonoma. | ||
*The 10-year event free [[survival rate]] is less than 51.6% with [[metastasis]] and 64.3% without metastasis. | *The 10-year event free [[survival rate]] is less than 51.6% with [[metastasis]] and 64.3% without [[metastasis]]. | ||
Additionally: | Additionally: | ||
Latest revision as of 16:44, 20 November 2017
|
Glucagonoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glucagonoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Glucagonoma natural history, complications and prognosis |
|
FDA on Glucagonoma natural history, complications and prognosis |
|
CDC on Glucagonoma natural history, complications and prognosis |
|
Glucagonoma natural history, complications and prognosis in the news |
|
Blogs on Glucagonoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Glucagonoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2], Mohammed Abdelwahed M.D[3]
Overview
If left untreated, patients with glucagonoma may progress to develop necrolytic migratory erythema, cheilosis, stomatitis, diarrhea, polyuria, and polydipsia. The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10-year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis. Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis. Age, grade, and distant metastases are the most significant predictors of survival.
Natural History
- If left untreated, patients with glucagonoma may progress to develop necrolytic migratory erythema, cheilosis, stomatitis, diarrhea, polyuria, and polydipsia.
- Glucagonoma has a very slow growth rate compared to most malignant tumors.
Complications
Complications of glucagonoma include:
- Metastasis:
- Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis.
- Metastasis occurs mainly in the liver but in few cases, it can occur in lymph nodes, peritoneum, lung, and adrenals.
- Weight loss: due to the catabolic effect of glucagon, most patients lose weight.
- Anemia
- Neuropsychiatric manifestations include depression, dementia, psychosis, and agitation
- Reversible dilated cardiomyopathy[1]
Prognosis
Prognosis of glucagonoma depends on the following:
- Whether or not the tumor can be removed by surgery.
- The stage of the tumor, the size of the tumor, whether cancer has spread outside the pancreas.
- The patient’s general health.
- Whether the tumor has just been diagnosed or has recurred.
- The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma.
- The 10-year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis.
Additionally:
- Age, grade, and distant metastases are the most significant predictors of survival.
- Five and 10-year survival rates for patients undergoing resection of gastroenteropancreatic neuroendocrine tumors.[2]
- Sixty percent of glucagonomas are malignant. Once the tumor is metastatic, the cure is rare.[3]
References
- ↑ K. Chang-Chretien, J. T. Chew & D. P. Judge. "Reversible dilated cardiomyopathy associated with glucagonoma". Heart (British Cardiac Society). 90 (7): e44. doi:10.1136/hrt.2004.036905. PMID 15201270.
- ↑ Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). "The glucagonoma syndrome. Clinical and pathologic features in 21 patients". Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.
- ↑ M. A. Chastain (2001). "The glucagonoma syndrome: a review of its features and discussion of new perspectives". The American journal of the medical sciences. 321 (5): 306–320. PMID 11370794. Unknown parameter
|month=ignored (help)